Health & Biotech
PharmAust Limited (ASX:PAA) is a clinical-stage biotechnology company developing therapeutics for human and animal health applications.
The company is focused on repurposing monepantel (MPL) for human neurodegenerative diseases and treating cancer in dogs. MPL is a potent and safe inhibitor of the mTOR pathway. This pathway plays a central role in cell growth and proliferation of cancer cells and degenerating neurons. The mTOR pathway regulates the cellular “cleaning process”, where toxic protein is broken down into macromolecules to be reused. This autophagic process is disrupted in most neurodegenerative diseases, including motor neurone disease (MND/ALS).
PAA’s lead MPL program is for the treatment of MND/ALS, a rare, incurable disease. The company is currently completing a Phase 1 study in patients with MND/ALS. PAA anticipates starting a Phase 2 study in H1 2024 that could lead to accelerated approval with the US Food and Drug Administration in 2026. PAA is preparing to start a pivotal field trial in dogs with B-Cell Lymphoma to enable product registration in the US in 2025. PAA has previously successfully completed a Phase 1 oncology clinical study of monepantel in humans and pilot studies in canine cancer.
KEY PEOPLE
RELATED STOCKHEAD STORIES
News
Market Highlights: US banks beat expectations, Merck Moderna breakthrough, and 5 ASX small caps to watch on Monday
Health & Biotech
PharmAust seeks experienced CEO to take its deep clinical trials pipeline to the next stage
News
Market Highlights: US inflation cools, plans for 10x increase in EV sales, and 5 ASX small caps to watch today
Health & Biotech
ASX Health Stocks: Cyclopharm sends reply to FDA, the final step before potential approval
Health & Biotech
PharmAust completes patient enrolment for MPL trial with sights on US$3.6 billion Motor Neurone Disease market
Health & Biotech
PharmAust’s MND trial progressing with ‘stable’ patient moving to higher dosage
Health & Biotech
ASX Biotech Stocks: Noxopharm eyes new mRNA product with market forecast to hit US$128 billion by 2030
Health & Biotech
Louie the beagle is beating the odds thanks to PharmAust’s canine cancer trial
Health & Biotech
PharmAust eyes Phase-3 trial after positive results from canine cancer drug
Health & Biotech
PharmAust’s interim analysis could set the stage for expedited Phase-2 MND trial
Health & Biotech
PharmAust lands key European patent for MPL combinations in cancer
Health & Biotech
PharmAust doses first MND patient in second cohort with larger MPL dose
Health & Biotech
PharmAust reports extension of survival time and quality of life from MPL trial for dogs with B-cell lymphoma
Stockhead TV
2023 Prepped and Primed: PharmAust (ASX:PAA) with general manager, Fiona Milner
Health & Biotech
PharmAust’s MND trial progresses to elevated MPL doses
News
Market Highlights: US stocks dip as debt ceiling disaster looms; and 5 ASX small caps to watch on Friday
Health & Biotech